Arbutus Q3 net loss $7.7M ($0.04/sh); cash $93.7M; imdusiran data positive

Arbutus Biopharma Corp

2025-Q3 EPS reported -$0.16 vs consensus -$0.03 ▼ miss (-406.3%)

Net loss of $7.7M ($0.04 per share) vs $19.7M ($0.10) in Q3 2024.
Revenue fell to $0.5M from $1.3M due to lower Alnylam ONPATTRO royalties.
Cash, equivalents and marketable securities $93.7M at Sep 30, 2025, down from $122.6M at Dec 31, 2024.
Moderna US trial set for March 2026; Pfizer-BioNTech claim construction ruling favorable in Sep 2025.
Imdusiran: 46% of Phase 2a patients discontinued all treatment; 94% of long-term follow-up off treatment up to 2+ years.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.